1.  6
    Institutional Responsibility and the Flawed Genomic Biomarkers at Duke University: A Missed Opportunity for Transparency and Accountability.David L. DeMets, Thomas R. Fleming, Gail Geller & David F. Ransohoff - 2017 - Science and Engineering Ethics 23 (4):1199-1205.
    When there have been substantial failures by institutional leadership in their oversight responsibility to protect research integrity, the public should demand that these be recognized and addressed by the institution itself, or the funding bodies. This commentary discusses a case of research failures in developing genomic predictors for cancer risk assessment and treatment at a leading university. In its review of this case, the Office of Research Integrity, an agency within the US Department of Health and Human Services, focused their (...)
    Direct download (2 more)  
    Export citation  
    Bookmark   4 citations  
  2.  26
    Statistics and Ethics in Medical Research.David L. DeMets - 1999 - Science and Engineering Ethics 5 (1):97-117.
    Ethical conduct is an essential component in research, especially in medical research. Statistical methods for design and analysis are powerful research tools if used properly. Abuse of these principles and methods are just as unethical as other laboratory or clinical misconduct. Inadequate research design can produce worthless results and thus wastes effort and valuable resources. For clinical research, patient resources are wasted. Inappropriate analysis of data can also produce misleading results and conclusions. For clinical research, inferior therapy might be given (...)
    Direct download (3 more)  
    Export citation  
    Bookmark   1 citation  
  3. No, Not Another IRBData Monitoring Committees in Clinical Trials: A Practical Perspective.Bruce Levin, Susan S. Ellenberg, Thomas R. Fleming & David L. DeMets - 2003 - IRB: Ethics & Human Research 25 (1):17.
    No categories
    Direct download (2 more)  
    Export citation